Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
日本語
English
Русский
中文
Español
Português
Deutsch
한국어
Français
Italiano
Türkçe
TCRX
#3152
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-3.64%
Monthly Change
-4.50%
6 month change
-43.32%
Year Change
-48.29%
Previous Close
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Volume
6
Markets
US Stock Market
Healthcare
TCRX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Dividends per share
—
—
—
—
—
Dividend yield %
—
—
—
—
—
Payout ratio %
—
—
—
—
—
News
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan Therapeutics株式、ASHイベント後もBTIGからニュートラル評価を維持
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
モルガン・スタンレー、臨床試験の遅延でTscan Therapeuticsを格下げ
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
【決算速報】Tscan Therapeutics、売上高は予想を上回り、利益は予想を上回る結果に